摘要
The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is anationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA;n-759), vancomycin-resistant Enterococcus faecium (VRE; n=191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n=602), ESBL-producing Klebsiella pneumoniae (n=736), and Acinetobacter baumannii (n=726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC 90 values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were
原文 | 英語 |
---|---|
頁(從 - 到) | 1414-1417 |
頁數 | 4 |
期刊 | Antimicrobial Agents and Chemotherapy |
卷 | 56 |
發行號 | 3 |
DOIs | |
出版狀態 | 已發佈 - 3月 2012 |
ASJC Scopus subject areas
- 藥理
- 藥學(醫學)
- 傳染性疾病